Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Open Access
- 1 May 2019
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (5) , e00021-19
Abstract
Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure tuberculosis (TB) in BALB/c mice compared to that of the first-line regimen and have yielded promising results in initial clinical trials. However, the independent contribution of the investigational new drug pretomanid to the efficacy of BPaMZ has not been examined, and its contribution to BPaL has been examined only over the first 2 months of treatment. In the present study, the addition of pretomanid to BL increased bactericidal activity, prevented emergence of bedaquiline resistance, and shortened the duration needed to prevent relapse with drug-susceptible isolates by at least 2 months in BALB/c mice. Addition of pretomanid to bedaquiline, moxifloxacin, and pyrazinamide (BMZ) resulted in a 1-log10 greater CFU reduction after 1 month of treatment and/or reduced the number of mice relapsing in each of 2 experiments in BALB/c mice and in immunocompromised nude mice. Bedaquiline-resistant isolates were found at relapse in only one BMZ-treated nude mouse. Treatment of infection with a pyrazinamide-resistant mutant in BALB/c mice with BPaMZ prevented selection of bedaquiline-resistant mutants and reduced the proportion of mice relapsing compared to that for BMZ treatment alone. Among severely ill C3HeB/FeJ mice with caseous pneumonia and cavitation, BPaMZ increased median survival (≥60 versus 21 days) and reduced median lung CFU by 2.4 log10 at 1 month compared to the level for BMZ. In conclusion, in 3 different mouse models, pretomanid contributed significantly to the efficacy of the BPaMZ and BPaL regimens, including restricting the selection of bedaquiline-resistant mutants.Keywords
All Related Versions
Funding Information
- Global Alliance for Tuberculosis Drug Development
- HHS | National Institutes of Health (R01-AI111992)
This publication has 34 references indexed in Scilit:
- Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Pathology of post primary tuberculosis of the lung: An illustrated critical reviewTuberculosis, 2011
- Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune-deficient MiceAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Treatment of Active Tuberculosis in HIV‐Coinfected Patients: A Systematic Review and Meta‐AnalysisClinical Infectious Diseases, 2010
- Rates and Mechanisms of Resistance Development inMycobacterium tuberculosisto a Novel Diarylquinoline ATP Synthase InhibitorAntimicrobial Agents and Chemotherapy, 2010
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- Bactericidal Activity of the Nitroimidazopyran PA-824 in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2005